Repare Therapeutics Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash Flows From Operating Activities:
Net loss for the year
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense
Depreciation expense
Loss on disposal of property and equipment
Non-cash lease expense
Foreign exchange loss
Net accretion of marketable securities
Deferred tax asset
Changes in operating assets and liabilities:
Prepaid expenses
Research and development tax credits receivable
Collaboration revenue receivable
Other current receivables
Other non-current assets
Accounts payable
Accrued expenses and other current liabilities
Operating lease liabilities, current portion
Income taxes
Operating lease liabilities, net of current portion
Deferred revenue
Net cash used in operating activities
Cash Flows From Investing Activities:
Purchase of property and equipment
Proceeds on disposal of property and equipment
Proceeds from maturities of marketable securities
Purchase of marketable securities
Net cash provided by investing activities
Cash Flows From Financing Activities:
Proceeds from exercise of stock options
Proceeds from issuance of common shares under the 2020 Employee Share Purchase Plan
Net proceeds from issuance of common shares in follow-on offering
Proceeds from issuance of warrant
Net proceeds from issuance of common shares in initial public offering
Net cash provided by financing activities

Effect of exchange rate fluctuations on cash held
Net Decrease In Cash And Cash Equivalents
Cash and cash equivalents cash at beginning of year
Cash and cash equivalents at end of year
Cash and cash equivalents
Restricted cash
Supplemental Disclosure Of Cash Flow Information:
Cash interest received
Cash taxes paid, net
Property and equipment purchases incurred but not yet paid
Right-of-use assets obtained in exchange for new operating lease liability
Conversion of Series A and B Preferred Shares into common shares
Conversion of warrant into common shares

Comments